Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters

Antimicrobial Agents and Chemotherapy
Efi KokkotouC P Kelly

Abstract

Clostridium difficile-associated colitis is an increasing cause of morbidity and mortality in hospitalized patients, with high relapse rates following conventional therapy. We sought to determine the efficacy of rifaximin, a novel nonabsorbed antibiotic, in the hamster model of C. difficile-associated diarrhea (CDAD). Hamsters received clindamycin subcutaneously and 24 h later were infected by gavage with one of two C. difficile strains: a reference strain (VPI 10463) and a current epidemic strain (BI17). Vancomycin (50 mg/kg of body weight) or rifaximin (100, 50, and 25 mg/kg) were then administered orally for 5 days beginning either on the same day as infection (prevention) or 24 h later (treatment). Therapeutic effects were assessed by weight gain, histology, and survival. We found that rifaximin was as effective as vancomycin in the prevention and treatment of colitis associated with the two C. difficile strains that we examined. There was no relapse after treatment with vancomycin or rifaximin in hamsters infected with the BI17 strain. Hamsters infected with the VPI 10463 strain and treated with rifaximin did not develop relapsing infection within a month of follow-up, whereas the majority of vancomycin-treated animals rel...Continue Reading

References

Jun 1, 1994·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·M M OlsonD N Gerding
Mar 1, 1994·The Journal of Clinical Investigation·C P KellyC Pothoulakis
Jan 27, 1994·The New England Journal of Medicine·C P KellyJ T LaMont
Apr 2, 1998·The Journal of Hospital Infection·M H WilcoxA Davidson
Jun 26, 1999·Alimentary Pharmacology & Therapeutics·P GionchettiM Campieri
Jun 10, 2000·Journal of Clinical Pharmacy and Therapeutics·F A Al-EidanM P Kearney
Aug 22, 2000·Antimicrobial Agents and Chemotherapy·C S McVay, R D Rolfe
Oct 6, 2001·Gastroenterology Clinics of North America·L KyneC P Kelly
Oct 10, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·F Barbut, J C Petit
May 23, 2002·Antimicrobial Agents and Chemotherapy·T PeláezE Bouza
Jul 24, 2002·The American Journal of Gastroenterology·Lynne V McFarlandChristina M Surawicz
Sep 20, 2002·Scandinavian Journal of Infectious Diseases·Sari TalShmuel Levi
Oct 4, 2002·Archives of Surgery·Arden M MorrisKaren E Deveney
Aug 2, 2003·Gastroenterology·Tor C SavidgeCharalabos Pothoulakis
Sep 1, 2004·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Jacques PépinDaniel Chouinard
Sep 25, 2004·Antimicrobial Agents and Chemotherapy·Pauline M AntonCharalabos Pothoulakis
Sep 29, 2004·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Loreen Pindera
Jan 28, 2005·Journal of Medical Microbiology·Maja RupnikChristoph von Eichel-Streiber
May 13, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Daniel M MusherRichard J Hamill
May 13, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jacques PepinClaude Bourassa
May 18, 2005·Annals of Internal Medicine·Herbert L DuPontFrancisco Martinez-Sandoval
Aug 27, 2005·The Lancet Infectious Diseases·Saima AslamDaniel M Musher
Dec 3, 2005·The New England Journal of Medicine·L Clifford McDonaldDale N Gerding
Apr 6, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David N TaylorA Louis Bourgeois
Apr 19, 2006·Gastroenterology·Seema Maroo, J Thomas Lamont
Nov 23, 2006·Annals of Internal Medicine·John G Bartlett
Feb 17, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stuart JohnsonDale N Gerding
Oct 11, 2007·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Judith A O'BrienDavid M Davidson

❮ Previous
Next ❯

Citations

Jun 10, 2009·British Medical Bulletin·O Martin Williams, Robert C Spencer
Jun 27, 2012·Antimicrobial Agents and Chemotherapy·Michelle M ButlerTerry L Bowlin
Dec 29, 2011·Antimicrobial Agents and Chemotherapy·Sofya DvoskinGeorge E Wright
May 31, 2012·Antimicrobial Agents and Chemotherapy·Anna TrzaskoDavid McKenney
Apr 3, 2009·World Journal of Gastroenterology : WJG·Perry Hookman, Jamie S Barkin
Jul 1, 2010·Expert Review of Anti-infective Therapy·Jessica CottreauKevin W Garey
Dec 9, 2015·Expert Review of Gastroenterology & Hepatology·David Padua, Charalabos Pothoulakis
Oct 17, 2008·Expert Opinion on Investigational Drugs·Joseph GuilesXicheng Sun
Mar 12, 2015·Journal of Medicinal Chemistry·Angie M JarradMatthew A Cooper
Jun 18, 2011·The Medical Clinics of North America·Luke F Chen, Donald Kaye
Nov 17, 2009·Infectious Disease Clinics of North America·Luke F Chen, Donald Kaye
May 22, 2009·Gastroenterology·Daniel A Leffler, J Thomas Lamont
Oct 14, 2008·Gastroenterology·Xinhua ChenCiarán P Kelly
May 5, 2012·Gut Microbes·Emma L BestMark H Wilcox
Sep 20, 2012·American Journal of Therapeutics·Josmi JosephSury Anand
Dec 3, 2016·Infectious Diseases and Therapy·Csaba FehérJosep Mensa
Aug 16, 2016·American Journal of Physiology. Gastrointestinal and Liver Physiology·Hon Wai KoonCharalabos Pothoulakis
Jul 18, 2018·Antimicrobial Agents and Chemotherapy·Amber HowertonErnesto Abel-Santos
May 21, 2010·Journal of Clinical Gastroenterology·Faith RohlkeNeil Stollman
Oct 12, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Marie HocquartMatthieu Million
Mar 31, 2021·Scientific Reports·Nader S Abutaleb, Mohamed N Seleem

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.